Multiplex Drug Assay Using Segmented Microparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multiplex assays for detecting drugs in bodily fluids face challenges such as cross-talk between antibodies and related drug conjugates, limiting their effectiveness for simultaneous and semi-quantitative analysis, especially in larger-scale automated testing.
Innovation Solution
The method involves using microparticles with magnetically responsive material, divided into subsets distinguishable by differentiation parameters, and coupled to analyte conjugates or primary antibodies, which are incubated with samples and labeled ligands, followed by magnetic separation and analysis by flow cytometry to determine the presence and semi-quantitative amounts of drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a multiplex assay is designed to detect multiple drugs simultaneously, then the testing time is reduced and productivity is improved, but cross-talk between antibodies and related drug conjugates increases, reducing measurement precision
Solution Approach 1:
The assay system is segmented into separate microparticle subsets, with each subset containing microparticles specific to a particular drug or drug class. This physical separation prevents cross-talk between different drug assays while maintaining simultaneous detection capability. Each microparticle subset is distinguishable by differentiation parameters, allowing independent analysis of multiple drugs in a single multiplex assay.
Solution Approach 2:
Different microparticle subsets are assigned different differentiation parameters (such as fluorescent tags, magnetic properties, or other detectable characteristics) that are locally specific to each drug target. This allows the system to maintain high measurement precision for each individual drug while conducting simultaneous multiplex testing, as each local region (microparticle subset) has optimized properties for its specific target.
2Measurement precision
If discrete tests are run for individual drugs, then measurement precision for each drug is maintained, but the time required for testing increases significantly
Solution Approach 1:
Multiple discrete drug tests are merged into a single multiplex assay by combining different microparticle subsets in one reaction system. Each subset maintains its own specific antibody conjugates and detection parameters, allowing simultaneous detection of multiple drugs with preserved measurement precision. The microparticles are magnetically separated and analyzed by flow cytometry to provide combined results from all drugs tested in parallel.
3Device complexity
If qualitative assays are used for drug detection, then the complexity of the assay is reduced, but the ability to perform semi-quantitative analysis is lost
Solution Approach 1:
The assay system utilizes detectable parameters (such as fluorescent intensity, magnetic signal strength, or other measurable properties) that can be quantitatively measured by flow cytometry. By changing the detection parameter from simple presence/absence to measurable signal intensity, the system enables semi-quantitative analysis while maintaining relatively simple assay architecture. The microparticle subsets provide a controlled system where signal intensity correlates with drug concentration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for simultaneous and semi-quantitative detection of multiple drugs in a single analysis, reducing cross-talk and improving precision, making it suitable for larger-scale automated testing.
Implementation Method 1
magnetically separating microparticles in all of said groups from said liquid medium
Implementation Method 2
analyzing said microparticles in said second liquid medium by flow cytometry and identifying analytes present in the sample
Implementation Method 3
incubating the product of step (a) with a liquid medium comprising one or more labeled ligands for the primary antibodies or the conjugates
Data Source
AI summary
Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.